Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1Breast 1

Conditions

Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Breast Neoplasms 3Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × bosutinib × Clear all
NCT00195260 2013-02-11

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Pfizer

Phase 1 Completed
151 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01001936 2009-10-27

Study Evaluating SKI-606 in Subject With Solid Tumors

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

NCT00777530 2008-10-23

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
48 enrolled
BreastOther hematologic neoplasm

Breast Neoplasms, Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡